- Home
- EXPE vs TAK Comparison
EXPE vs TAK Comparison
Compare EXPE & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EXPE | TAK |
|---|---|---|
| Founded | 1996 | 1781 |
| Country | United States | Japan |
| Employees | N/A | N/A |
| Industry | Transportation Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.7B | 43.3B |
| IPO Year | 1999 | N/A |
Fundamental Metrics
Financial Performance| Metric | EXPE | TAK |
|---|---|---|
| Price | $285.63 | $16.16 |
| Analyst Decision | Buy | |
| Analyst Count | 28 | 0 |
| Target Price | ★ $271.85 | N/A |
| AVG Volume (30 Days) | 1.4M | ★ 2.6M |
| Earning Date | 02-12-2026 | 01-29-2026 |
| Dividend Yield | 0.56% | ★ 3.27% |
| EPS Growth | ★ 35.97 | N/A |
| EPS | ★ 10.37 | 0.14 |
| Revenue | $14,370,000,000.00 | ★ $29,846,840,032.00 |
| Revenue This Year | $8.74 | N/A |
| Revenue Next Year | $7.26 | $0.47 |
| P/E Ratio | ★ $27.49 | $226.88 |
| Revenue Growth | ★ 7.29 | N/A |
| 52 Week Low | $130.01 | $12.80 |
| 52 Week High | $303.80 | $16.48 |
Technical Indicators
Market Signals| Indicator | EXPE | TAK |
|---|---|---|
| Relative Strength Index (RSI) | 52.04 | 63.86 |
| Support Level | $281.45 | $15.87 |
| Resistance Level | $300.31 | $16.48 |
| Average True Range (ATR) | 7.88 | 0.19 |
| MACD | -1.66 | 0.01 |
| Stochastic Oscillator | 37.31 | 66.00 |
Price Performance
Historical ComparisonAbout EXPE Expedia Group Inc.
Expedia is the world's second-largest online travel agency by bookings, offering services for lodging (80% of total 2024 sales), air tickets (3%), rental cars, cruises, in-destination, and other (10%), and advertising revenue (7%). Expedia operates a number of branded travel booking sites, but its three core online travel agency brands are Expedia, Hotels.com, and alternative accommodations brand Vrbo. It also has a metasearch brand, Trivago. Transaction fees for online bookings account for the bulk of sales and profits.
About TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.